Effects of Soy Protein on Serum paraoxonase1 Activity and Lipoproteins in Postmenopausal Women

This study has been completed.
Sponsor:
Information provided by:
Iran University of Medical Sciences
ClinicalTrials.gov Identifier:
NCT00457262
First received: April 4, 2007
Last updated: NA
Last verified: March 2007
History: No changes posted
  Purpose

paraoxonase 1 is involved to prevent LDL and HDL oxidation,so increase of it's activity leads to lower risk of coronary heart disease.In postmenopausal women ,we have decrease of paraoxonase1 activity and soy proteins may increase paraoxonase1 activity


Condition Intervention
Postmenopausal
Hyperlipidemia
Procedure: soy consumption

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Parallel Assignment
Masking: Double-Blind
Primary Purpose: Prevention
Official Title: Effects of Soy Protein on Serum paraoxonase1 Activity and Lipoproteins in Postmenopausal Women

Resource links provided by NLM:


Further study details as provided by Iran University of Medical Sciences:

Primary Outcome Measures:
  • decrease of LDL,increase of HDL,increase of paraoxonase 1

Estimated Enrollment: 42
Study Start Date: January 2006
Study Completion Date: August 2006
Detailed Description:

In a double blind clinical randomised clinical trial with parallel design this study was done.52 postmenopausal women were randomly assigned to 50 g/d soy protein or placebo for 10 weeks.serum lipoproteins and pon1 activity were measured at baseline and 10th week.There were significant increase in PON! activity and significant decrease in LDL-C,LDL-C/HDL-C,TC/HDL-C and TG/HDL-C in soy group compare to placebo group.

  Eligibility

Ages Eligible for Study:   51 Years to 57 Years
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Cessation of menes for more than 1 year, elevation for more than 1 year
  • Elevation of FSH level
  • Total cholesterol
  • Triglyceride more than 200 mg/dl

Exclusion Criteria:

  • Chronic disease (heart disease, cancer, diabetes, hepatic, kidney and thyroid disease)
  • Antihypertensive drugs
  • Antibiotics
  • Lipid lowering drugs
  • Sex hormone treatment
  • Hysterectomy
  • Diet rich in soy protein
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00457262

Sponsors and Collaborators
Iran University of Medical Sciences
Investigators
Study Chair: farzad Shidfar, Ph.D assistant professor of nutrition,Iran university of medical sciences
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00457262     History of Changes
Other Study ID Numbers: 1344
Study First Received: April 4, 2007
Last Updated: April 4, 2007
Health Authority: Iran: Ethics Committee

Keywords provided by Iran University of Medical Sciences:
paraoxonase1 activity
LDL
HDL
postmenopausal women
postmenopausal women and hyperlipidemia

Additional relevant MeSH terms:
Hyperlipidemias
Dyslipidemias
Lipid Metabolism Disorders
Metabolic Diseases

ClinicalTrials.gov processed this record on September 14, 2014